• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Comparison of Clevidipine and Nicardipine for Acute Blood Pressure Reduction in Hemorrhagic Stroke
ConclusionsIn patients with hemorrhagic stroke, nicardipine appeared to have similar efficacy as clevidipine in SBP reduction, with a more likely reduction of rebound hypertension and drug cost. This retrospective study was underpowered, which may limit these implications. Further prospective studies are warranted to confirm these results.
Source: Neurocritical Care - December 13, 2021 Category: Neurology Source Type: research

New XARELTO ® (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Program to be Unveiled at American Heart Association (AHA) Scientific Sessions 2020
RARITAN, N.J., November 9, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that 10 data presentations will be shared at the virtual American Heart Association (AHA) Scientific Sessions 2020 from November 13-17. Most notably, four new sub-analyses of XARELTO® (rivaroxaban) from the landmark VOYAGER PAD trial, part of the EXPLORER global cardiovascular research program, will be presented, including two live, featured science oral presentations. “We're pleased VOYAGER PAD was selected to be front and center once again at a major medical congress, as there's an urgent need for data in ...
Source: Johnson and Johnson - November 9, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Clinical Features and Risk Factors of Mortality in Patients with Posterior Reversible Encephalopathy Syndrome
CONCLUSIONS: Our results indicate that PRES could be considered as a sign of a very high-risk patient. We also demonstrated that heart failure and stroke were independent risk factors for death in patients with PRES; moreover, pregnancy was a protective factor.PMID:36419591 | PMC:PMC9678458 | DOI:10.1155/2022/9401661
Source: Behavioural Neurology - November 24, 2022 Category: Neurology Authors: Hong-Wei Cui Ru-Yi Lei Bo-Ai Zhang Source Type: research

Pregnancy Is Scary Enough Without Having To Worry That a Catholic Hospital Might Turn You Away
Maybe I'm just more attuned to it these days -- your 30s will do that to you -- but lately it feels like everyone I know has a scary story about pregnancy. After the adorable photographs have been posted, the celebratory texts sent, the welcome-back-to-the-world-of-sushi-and-beer meals eaten, they tell you about the darker parts of the experience. The nightmarishly long labor. The NICU. The miscarriages that sometimes came before. The last thing any of these women should have to worry about -- the last thing anyone who is pregnant, or their family, should have to worry about -- is being denied appropriate medical care be...
Source: Healthy Living - The Huffington Post - May 9, 2016 Category: Consumer Health News Source Type: news

Etiology and Outcomes of Thrombotic Microangiopathies.
CONCLUSIONS: Secondary thrombotic microangiopathies represent the majority of thrombotic microangiopathies. Multiple thrombotic microangiopathies causes are present in one half of secondary thrombotic microangiopathies. The risks of dialysis, neurologic and cardiac complications, and death vary by the cause of thrombotic microangiopathies. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2019_03_12_CJASNPodcast_19_04_.mp3. PMID: 30862697 [PubMed - as supplied by publisher]
Source: Clinical Journal of the American Society of Nephrology : CJASN - March 11, 2019 Category: Urology & Nephrology Authors: Bayer G, von Tokarski F, Thoreau B, Bauvois A, Barbet C, Cloarec S, Mérieau E, Lachot S, Garot D, Bernard L, Gyan E, Perrotin F, Pouplard C, Maillot F, Gatault P, Sautenet B, Rusch E, Buchler M, Vigneau C, Fakhouri F, Halimi JM Tags: Clin J Am Soc Nephrol Source Type: research

Anticoagulation in special patient populations with atrial fibrillation
Herz. 2021 Jul 5. doi: 10.1007/s00059-021-05042-1. Online ahead of print.ABSTRACTAnticoagulation in patients with atrial fibrillation (AF) should be guided by considerations of the risk of thromboembolism, stroke, and bleeding as well as the patient's preference. Well-recognized scores have been developed to help the clinician in daily risk assessment, but there are several special patient populations for whom scores are not developed or validated. Furthermore, these patients were not adequately represented in the pivotal randomized trials for non-vitamin K antagonist oral anticoagulants (NOACs). In patients with cancer, t...
Source: Herz - July 5, 2021 Category: Cardiology Authors: Laura Ueberham Gerhard Hindricks Source Type: research